Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant CD33 (Gemtuzumab Biosimilar) anticorps

Cet anticorps anti-CD33 (Gemtuzumab Biosimilar) est un anticorps Humanized Monoclonal détectant CD33 (Gemtuzumab Biosimilar) dans FACS et in vivo. Adapté pour Humain.
N° du produit ABIN7795111

Aperçu rapide pour Recombinant CD33 (Gemtuzumab Biosimilar) anticorps (ABIN7795111)

Antigène

CD33 (Gemtuzumab Biosimilar)

Type d'anticorp

Recombinant Antibody

Reactivité

Humain

Hôte

  • 3
  • 1
  • 1
  • 1
  • 1
Humanized

Clonalité

  • 4
  • 3
Monoclonal

Conjugué

  • 6
  • 1
Cet anticorp CD33 (Gemtuzumab Biosimilar) est non-conjugé

Application

  • 5
  • 3
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité

Research Grade
  • Expression System

    Mammalian cells

    Fonction

    Gemtuzumab Biosimilar, CD33 Monoclonal Antibody

    Attributs du produit

    Gemtuzumab is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50 % of the antibody loaded with 4-6 Moles calicheamicin per mole of antibody Label. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Gemtuzumab is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Gemtuzumab with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical. Eventually, cell death is induced.

    Purification

    Protein A or G affinity column

    Pureté

    >95 % by reducing SDS-PAGE

    niveau d'endotoxine

    < 1 EU per 1 mg of the protein by the LAL method

    Immunogène

    Human CD33
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    > 3 mg/mL

    Stock

    4 °C,-20 °C

    Stockage commentaire

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • Antigène

    CD33 (Gemtuzumab Biosimilar)

    Autre désignation

    Gemtuzumab Biosimilar

    Classe de substances

    Biosimilar
Vous êtes ici:
Chat with us!